Sandbox W00
From Proteopedia
(Difference between revisions)
| Line 24: | Line 24: | ||
Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | ||
| - | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). | + | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). <ref name='harel'/> |
<scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | <scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | ||
| Line 33: | Line 33: | ||
Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | ||
| - | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). <ref | + | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). <ref name='harel'/> |
<scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | <scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | ||
| Line 42: | Line 42: | ||
Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | ||
| - | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). | + | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). <ref name='harel'/> |
<scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | <scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | ||
| Line 51: | Line 51: | ||
Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | ||
| - | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). | + | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). <ref name='harel'/> |
<scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | <scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | ||
| Line 60: | Line 60: | ||
Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | ||
| - | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). | + | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). <ref name='harel'/> |
<scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | <scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | ||
| Line 78: | Line 78: | ||
Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | ||
| - | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). | + | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). <ref name='harel'/> |
<scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | <scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | ||
| Line 87: | Line 87: | ||
Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | ||
| - | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). | + | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). <ref name='harel'/> |
<scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | <scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | ||
| Line 96: | Line 96: | ||
Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | ||
| - | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). | + | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). <ref name='harel'/> |
<scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | <scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | ||
| Line 105: | Line 105: | ||
Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | Tacrine is a reversible inhibitor of cholinesterase. It was the first FDA approved drug for the treatment of Alzheimer's disease. | ||
| - | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). | + | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 (W84 and F330). <ref name='harel'/> |
<scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | <scene name='70/703975/Mytacrine/1'>TextToBeDisplayed</scene> | ||
Revision as of 07:46, 7 June 2015
Your Heading Here (maybe something like 'Structure')
| |||||||||||
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9031-5. PMID:8415649
- ↑ Rubinstein MH. A new granulation method for compressed tablets [proceedings]. J Pharm Pharmacol. 1976 Dec;28 Suppl:67P. PMID:12345
- ↑ Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9031-5. PMID:8415649
